Developing science,
delivering therapies


Our company

We are pioneers in harnessing bacteria as a revolutionary new class of medicines – called live biotherapeutics.

Our approach

Developing science

From asthma to cancer, we conduct world-leading research to identify live biotherapeutics with drug-like functionality to treat a range of diseases.

What we do

Delivering therapies

We are uniquely positioned to rapidly translate our research into regulated, safe and efficacious therapies for patients.

Find out more


4D pharma management will present and meet with investors at three upcoming investor conferences throughout March 2021.
4D pharma announces the appointment of Paul Maier as Non-Executive Director of the Board. Mr Maier will also be a member of 4D's Audit and Risk Committee and will serve as the Company's "audit committee financial expert" under SEC and Nasdaq rules.
4D pharma announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Company's management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.